Japan Approves Keytruda’s 1st Line RCC, Head and Neck Cancer Use, Bavencio’s Label Expansion and More

The Ministry of Health, Labor and Welfare (MHLW) approved a batch of new indications on December 20, including first-line use in advanced renal cell carcinoma (RCC) for the immune checkpoint inhibitors Bavencio (avelumab) and Keytruda (pembrolizumab), with the MSD drug...read more